The Involvement of Nano-Drug Delivery in Biosafety Issues
- Autores
- Romero, Eder Lilia
- Año de publicación
- 2012
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’.
Fil: Romero, Eder Lilia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
BIOSAFETY
DRUG DELIVERY SYSTEMS
NANOPARTICLES - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/195353
Ver los metadatos del registro completo
| id |
CONICETDig_52acced3769985fdebee466e17df191c |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/195353 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
The Involvement of Nano-Drug Delivery in Biosafety IssuesRomero, Eder LiliaBIOSAFETYDRUG DELIVERY SYSTEMSNANOPARTICLEShttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’.Fil: Romero, Eder Lilia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaOMICS GROUP2012-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/195353Romero, Eder Lilia; The Involvement of Nano-Drug Delivery in Biosafety Issues; OMICS GROUP; Biosafty; 1; 2; 3-2012; 1-52167-0331CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.longdom.org/open-access/the-involvement-of-nanodrug-delivery-in-biosafety-issues-2167-0331.1000e108.pdfinfo:eu-repo/semantics/altIdentifier/doi/10.4172/2167-0331.1000e108info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-11-12T09:46:15Zoai:ri.conicet.gov.ar:11336/195353instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-11-12 09:46:16.01CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
The Involvement of Nano-Drug Delivery in Biosafety Issues |
| title |
The Involvement of Nano-Drug Delivery in Biosafety Issues |
| spellingShingle |
The Involvement of Nano-Drug Delivery in Biosafety Issues Romero, Eder Lilia BIOSAFETY DRUG DELIVERY SYSTEMS NANOPARTICLES |
| title_short |
The Involvement of Nano-Drug Delivery in Biosafety Issues |
| title_full |
The Involvement of Nano-Drug Delivery in Biosafety Issues |
| title_fullStr |
The Involvement of Nano-Drug Delivery in Biosafety Issues |
| title_full_unstemmed |
The Involvement of Nano-Drug Delivery in Biosafety Issues |
| title_sort |
The Involvement of Nano-Drug Delivery in Biosafety Issues |
| dc.creator.none.fl_str_mv |
Romero, Eder Lilia |
| author |
Romero, Eder Lilia |
| author_facet |
Romero, Eder Lilia |
| author_role |
author |
| dc.subject.none.fl_str_mv |
BIOSAFETY DRUG DELIVERY SYSTEMS NANOPARTICLES |
| topic |
BIOSAFETY DRUG DELIVERY SYSTEMS NANOPARTICLES |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/2.10 https://purl.org/becyt/ford/2 |
| dc.description.none.fl_txt_mv |
Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’. Fil: Romero, Eder Lilia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
| description |
Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’. |
| publishDate |
2012 |
| dc.date.none.fl_str_mv |
2012-03 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/195353 Romero, Eder Lilia; The Involvement of Nano-Drug Delivery in Biosafety Issues; OMICS GROUP; Biosafty; 1; 2; 3-2012; 1-5 2167-0331 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/195353 |
| identifier_str_mv |
Romero, Eder Lilia; The Involvement of Nano-Drug Delivery in Biosafety Issues; OMICS GROUP; Biosafty; 1; 2; 3-2012; 1-5 2167-0331 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.longdom.org/open-access/the-involvement-of-nanodrug-delivery-in-biosafety-issues-2167-0331.1000e108.pdf info:eu-repo/semantics/altIdentifier/doi/10.4172/2167-0331.1000e108 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
OMICS GROUP |
| publisher.none.fl_str_mv |
OMICS GROUP |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1848597876940210176 |
| score |
12.976206 |